The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals

This study has been withdrawn prior to enrollment.
Information provided by:
Bayside Health Identifier:
First received: December 7, 2009
Last updated: November 7, 2011
Last verified: November 2011

The purpose of this study is to determine the effect of slowing heart rate upon both central and peripheral blood pressures using a medication called Ivabradine which slows heart rate without affecting heart contraction, and to compare the effects of ivabradine to a traditional blood pressure lowering medication called metoprolol (which is a beta-blocker).

Condition Intervention Phase
Blood Pressure
Drug: ivabradine
Drug: metoprolol
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals

Resource links provided by NLM:

Further study details as provided by Bayside Health:

Primary Outcome Measures:
  • central and peripheral arterial and pulse wave velocity [ Time Frame: baseline, and 4 hours following the administration of placebo, metoprolol or ivabradine. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Central pulse pressure [ Time Frame: Baseline measurements of central and peripheral arterial and pulse wave velocity will be made at baseline, and 4 hours following the administration of either placebo, metoprolol or ivabradine. ] [ Designated as safety issue: No ]

Estimated Enrollment: 42
Study Start Date: October 2008
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ivabradine Drug: ivabradine
Experimental: metoprolol Drug: metoprolol
Placebo Comparator: placebo Drug: placebo


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 18 - 25 years OR
  • Aged > 60 years

Exclusion Criteria

  • Chronic disease
  • Unable to give informed consent
  • Treated or untreated systemic arterial hypertension (SBP > 160 mmHg and/or DBP > 90 mmHg)
  • Resting bradycardia (heart rate < 60 beats/minute)
  • Pregnancy or active lactation
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Prof Bronwyn Kingwell, Baker IDI Heart & Diabetes Institute Identifier: NCT01029223     History of Changes
Other Study ID Numbers: 141/07
Study First Received: December 7, 2009
Last Updated: November 7, 2011
Health Authority: Australia: Therapeutic Goods Administration

Additional relevant MeSH terms:
Metoprolol succinate
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 15, 2014